What is BostonGene?
BostonGene operates at the intersection of artificial intelligence and clinical oncology, providing advanced molecular and immune profiling services. Its core offering, the BostonGene Tumor Portrait, delivers a comprehensive analysis of a patient's tumor microenvironment, identifying actionable mutations and biomarkers that inform personalized treatment pathways. By integrating complex biological data into a clear roadmap for clinicians, the company aims to improve patient outcomes while optimizing the economic efficiency of cancer care. This approach positions BostonGene as a pivotal player in the transition toward data-informed, patient-specific therapeutic strategies.
How much funding has BostonGene raised?
BostonGene has raised a total of $200M across 2 funding rounds:
Series A
$50M
Series B
$150M
Series A (2019): $50M, investors not publicly disclosed
Series B (2022): $150M led by NEC Corporation, Japan Industrial Partners, and Impact Investment Capital
Key Investors in BostonGene
Japan Industrial Partners
Japan Industrial Partners, Inc. is an investment fund that supports the revitalization of businesses in Japan, providing capital and management support for corporate restructuring and business carve-outs.
NEC Corporation
A multinational information technology and electronics corporation that invests in innovative technologies to drive digital transformation across various sectors.
Impact Investment Capital
An investment firm focused on deploying capital into ventures that generate measurable social and economic impact alongside financial returns.
What's next for BostonGene?
With the recent influx of capital, BostonGene is well-positioned to accelerate its research and development initiatives, focusing on the expansion of its AI-driven diagnostic platform. The strategic roadmap likely involves scaling the deployment of its Tumor Portrait tests across international markets and deepening partnerships with pharmaceutical entities to streamline clinical trial recruitment. As the company matures, the focus will shift toward integrating its diagnostic insights into standard clinical workflows, thereby cementing its role as an essential infrastructure provider for the future of personalized oncology. The firm's ability to leverage this financing will be instrumental in maintaining its competitive edge in the rapidly evolving digital health ecosystem.
See full BostonGene company page
